Matica Biotechnology Partners with KaliVir on Oncolytic Virus Manufacturing

• Matica Biotechnology Inc. and KaliVir Immunotherapeutics sign a Letter of Intent (LOI) to develop viral vector production for cancer therapies.

• The collaboration aims to advance manufacturing for KaliVir’s oncolytic virus, VET3-TGI, using Matica’s proprietary MatiMax cell line.

Matica Biotechnology Inc., a contract development and manufacturing organization (CDMO) focused on viral vector production, has formalized a partnership with KaliVir Immunotherapeutics, a clinical-stage biotech company specializing in cancer therapies. The two companies signed a Letter of Intent (LOI) for developing manufacturing processes for KaliVir’s oncolytic virus product.

Based in the United States, KaliVir is developing innovative oncolytic viral immunotherapies using its Vaccinia Enhanced Template (VET) platform. This technology facilitates the expression and systemic delivery of multiple therapeutic genes. KaliVir’s lead candidate, VET3-TGI, is designed to express interleukin-12 and inhibit TGFbeta, targeting immune regulation in cancer treatment.

Under the partnership, Matica Bio will employ its proprietary MatiMax cell line to establish a new viral vector production process for KaliVir. The collaboration seeks to enhance manufacturing efficiencies for the oncolytic virus and support product quality as it moves through various development phases.

“Our collaboration with Matica Bio allows us to accelerate the development of our oncolytic virus therapies. This agreement is expected to expand our strategic partnership across all phases of product development,” said Helena Chaye, CEO of KaliVir.

Paul Kim, CEO of Matica Bio, added, “The development of production processes for viral vectors is crucial for the stable production of high-quality therapeutics. Through this agreement, we aim to leverage our high-performance MatiMax cell line and CGT manufacturing expertise to actively support KaliVir’s oncolytic virus program.”